Clinical trials: Adrenal Cushing Syndrome
Cushing Syndrome
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome.
- Trial name
- NCT03053271
- Testing
- ATR-101
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 4 people
- Sponsor
- Millendo Therapeutics US, Inc.
Cushing's Syndrome
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
The purpose of this prospective, international phase III/IV study is to assess the efficacy and safety of metyrapone in patients with endogenous Cushing's syndrome during up to 36 weeks of treatment.
- Trial name
- PROMPT (NCT02297945)
- Testing
- metyrapone
- Where
- 36 sites in Belgium, Germany and 6 more
- Volunteers
- 50 people
- Sponsor
- HRA Pharma
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Hypercorticism
Patient and Partner Perception After Remission of Cushing's Syndrome
Hypercortisolism leads to long term physical and cognitive sequelae. This also holds true for quality of life, even several years after remission.
- Trial name
- CUSHING (NCT03607474)
- Testing
- Questionnaires of life quality for patients, Questionnaires of life quality for caregivers
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with…
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Trial name
- IMPACT-MACS (NCT07361874)
- Testing
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Cushing Syndrome
Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
This is a non-interventional, prospective, multinational, multicentre, observational study, in which data collected are those derived from routine clinical practice via an European registry on CS: ERCUSYN.
- Trial name
- KetoPASS (NCT04872920)
- Where
- 6 sites in Croatia, France and 2 more
- Volunteers
- 200 people
- Sponsor
- HRA Pharma
Cushing's Disease, Cushing Syndrome
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes.
- Conditions
- Cushing's Disease, Cushing Syndrome, Cushing Disease
- Trial name
- NCT03364803
- Testing
- Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS)
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adrenal Tumors, Adrenocortical Carcinoma
Adrenal Tumors - Pathogenesis and Therapy
The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates…
- Conditions
- Adrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome
- Trial name
- NCT00669266
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Wuerzburg
Cushing's Syndrome, Adrenal Incidentalomas
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
Background: The evaluation for hypercortisolism includes an overnight 1mg dexamethasone (DXM) suppression test. An important shortcoming is the diagnostic specificity of only 80%, which is likely due to inter-individual…
- Conditions
- Cushing's Syndrome, Adrenal Incidentalomas, Alcoholism, Obesity
- Trial name
- DXM (NCT01504555)
- Where
- 4 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital
Osteoporosis in Cushing's Syndrome, Osteoporosis in Post-menopausal Women
Cushing's Osteoporosis Specificities
Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of…
- Trial name
- SOCS (NCT03162068)
- Testing
- Osteodensitometry and pQCT
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Cushing Syndrome, Adrenal Insufficiency
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
This is a multicentric, prospective, intervention study on circadian genes expression in peripheral blood mononuclear cells as biomarkers of circadian rhythm derangement in patients affected by alterations of endogenous…
- Conditions
- Cushing Syndrome, Adrenal Insufficiency, Cushing Disease, Addison Disease
- Trial name
- CHROnOS (NCT04374721)
- Testing
- circadian gene expression evaluation
- Where
- Italy
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Adrenal Gland Hyperfunction, Cardiovascular Disease
Heart Disease Risk Factors in Major Depression
A series of studies in patients with major depression have consistently demonstrated a doubling of the mortality rate at any age, independent of suicide.
- Conditions
- Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
- Trial name
- NCT00001969
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
ACTH, Cushing's Syndrome
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess.
- Trial name
- NCT02019706
- Testing
- DOTATATE PET-CT, F-DOPA PET CT, CT scan
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypercortisolism, Arterial Hypertension
Cortisol Secretion, Sensitivity and Activity and Hypertension
The goal of this observational study is to evaluate, between patients with arterial hypertension and non hypertensive control group, the prevalence of hidden hypercortisolism the relationship between organ damage and oxidative…
- Trial name
- PRECOR (NCT05766085)
- Testing
- Dexamethasone suppression test
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- Istituto Auxologico Italiano
Resistant Hypertension, Hypercortisolism
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United…
- Trial name
- MOMENTUM (NCT06829537)
- Where
- 50 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
Diagnostic Performance of Screening Tests for Cushing s Syndrome
This study will test the accuracy of screening tests for Cushing s syndrome in overweight people with signs of the disorder. Cushing s syndrome is a rare disorder caused by excess production of the hormone cortisol.
- Trial name
- NCT00361777
- Where
- 2 sites in United States
- Volunteers
- 471 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Syndrome
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.
- Trial name
- RE-KLAIM (NCT02663609)
- Testing
- No intervention
- Volunteers
- 24 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Cushing Syndrome
Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure
In this study, we aimed to determine a specific cut-off value for 1mg DST to prevent false positivity usually seen in CRF patients according to the standard cut-off value of 1.8 mcg/dl.
- Trial name
- NCT05568602
- Testing
- Dexamethasone suppression test
- Where
- Turkey (Türkiye)
- Volunteers
- 1,034 people
- Sponsor
- Marmara University